Posted by Michael Wonder on 14 Aug 2019
U.S. law makers push Mylan, Teva over drug pricing probe
14 August 2019 - The head of the U.S. House of Representative’s oversight panel on Wednesday called on three drug makers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of “apparent efforts to stonewall” the probe.
U.S. House Oversight Chairman Elijah Cummings, along with U.S. Senator Bernie Sanders, the ranking member on the Senate Budget Committee, sent the letters to Mylan, Teva Pharmaceutical Industries and privately held Heritage Pharmaceuticals, the law makers said in a statement.
Mylan denied obstructing the inquiry and said it was prepared to make its case in a court of law, while Teva said it continues to fully cooperate with the investigations.
